$SHC

Sotera Health Co

alphai earnings readQ2 FY2026 · AUG 6Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 OutlookVerdict: strong

Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.

No enriched coverage for $SHC in the last 7 days.

$21.2M
Petras Michael B. Jr.
0%
See all $SHC insider activity →

SHC sentiment & insider activity

Recent SHC coverage spans earnings, insider activity and financial news.

In the last 30 days, SHC insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($21.2M). The most active reporter was Petras Michael B. Jr., Executive Chairman, with 2 filings.

What's driving SHC

alphai scores every news story that mentions SHC with an AI model for sentiment and relevance, and aggregates insider trades from Sotera Health Co's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $SHC

Score
$AVTRMed

Q2 Earnings Highs And Lows: Thermo Fisher (NYSE:TMO) Vs The Rest Of The Research Tools & Consumables Stocks

Avantor (AVTR) reported Q2 revenue of $1.69B, flat YoY, beating estimates by 4.9%, with stock up 8.2%. Bruker (BRKR) reported $838.5M revenue, up 5.2% YoY, missing estimates by 1.9%, with stock down 11.6%. Sotera Health (SHC) reported $321.4M revenue, up 9.2% YoY, beating estimates by 3.8%, with stock up 2.9%. Bio-Techne (TECH) reported $321.2M revenue, up 1.3% YoY, beating estimates by 2%, with stock flat.

$SHCMed

What Sotera Health (SHC)'s Strong Q2 Beat and Raised Outlook Means For Shareholders

Sotera Health (SHC) reported Q2 2026 revenue of $321.38 million, up from $294.34 million, and net income of $53.64 million versus $7.96 million a year earlier. The company cited strength across Sterigenics, Nordion, and Nelson Labs and raised its full-year outlook. The article also notes a May 2026 repricing of first lien term loans and discusses regulatory and litigation risks tied to ethylene oxide.

$SHCLow

Sotera Health Co (SHC): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Sotera Health Co (SHC) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 11, 2026, James C. Neary notified the Board of Directors (the “Board”) of Sotera Health Company (the “Company”)

$SHCLow

China’s ‘brain chip’ drive accelerates with slew of state-backed initiatives

China is accelerating brain-computer interface (BCI) development via state-backed initiatives. PICC Property and Casualty, a state-owned insurer, said it signed China’s first commercial insurance policy covering invasive BCI implant surgery, with a hospital affiliated with Zhejiang University in Hangzhou. BCI-linked Hong Kong stocks rose 1.59% on Wednesday, including Shanghai Heartcare (+1.28%) and BrainAurora (+1.65%).

$SHCMed

Sotera Health Company (SHC) Reported Positive Results Amid Litigation Wins

McIntyre Partnerships’ Q2 2026 investor letter highlighted Sotera Health (NASDAQ:SHC). It cited Sterigenics returning to HSD organic growth, Georgia litigation where a judge dismissed 5 lawsuits, and a CEO transition. The article notes SHC closed at $18.86 on Aug. 7, 2026, and discusses an estimated sub-$50M current liability and ~$180M worst-case settlement versus ~$640M 2026 EBITDA.

$SHCMed

SHC Q2 Deep Dive: Broad-Based Growth, Leadership Transition, and Strategic Investments Shape Outlook

Sotera Health’s management said Q2 results reflected execution across Sterigenics, Nordion and Nelson Labs, helped by improved pricing and capacity investments. It completed a CEO transition, with Alton Shader replacing Michael Petras. Sterigenics demand was stable, Nordion benefited from Cobalt-60 shipment timing, and Nelson Labs gained from new customer projects. Guidance cites volume growth, inflation and litigation risks.

Related tickers